Triazoles as NR2B receptor inhibitors

US10323021B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Rudolf Schindler · Dresden, DE
• Hans-Joachim Lankau · Weinböhla, DE
• Norbert Höfgen · Radeberg, DE
• Ute Egerland · Radebeul, DE
• Barbara Langen · Radebeul, DE
• Rita Dost · Dresden, DE
• Simon Edward Ward · Peacehaven, GB

Key dates

• Filing date: Apr 27, 2018
• Grant date: Jun 18, 2019
• Expiry date: Apr 27, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D249/08
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided here in are compounds of Formula I having the structure: Also provided herein are compositions comprising compounds of Formula I and methods of using compounds of Formula I for the treatment of disorders, diseases or conditions mediated by GluN2B receptors.